Kazia Therapeutics Annual Report 2021

STATEMENT OF CHANGES IN EQUITY (CONTINUED) For the year ended 30 June 2021 40 Kazia Therapeutics Limited 0 Annual Report 2021 Contributed equity Other contributed equity Foreign currency translation reserve Share based payments reserve Accumulated losses Total equity Consolidated $ $ $ $ $ $ Balance at 1 July 2020 48,781,214 464,000 (455,188) 1,521,111 (36,185,557) 14,125,580 Loss after income tax benefit for the year - - - - (8,421,960) (8,421,960) Other comprehensive income for the year, net of tax - - 1,868 - - 1,868 Total comprehensive income for the year - - 1,868 - (8,421,960) (8,420,092) Shares issued (note 17) 32,908,949 - - - - 32,908,949 Share issue costs (note 17) (1,673,388) - - - - (1,673,388) Transactions with owners in their capacity as owners: Issue of shares on exercise of options 273,287 - - (80,353) 80,353 273,287 Share based payment (note 32) - - - 636,383 - 636,383 Expired options - - - (323,255) 323,255 - Balance at 30 June 2021 80,290,062 464,000 (453,320) 1,753,886 (44,203,909) 37,850,719 The above statement of changes in equity should be read in conjunction with the accompanying notes